TABLE II.
Patient Characteristics
| Characteristics | HCV monoinfected (n = 58) | HIV/HCV co-infection (n = 65) | P-value* |
|---|---|---|---|
| Age (year) | 43.9 (10.2) | 47.0 (7.6) | NS |
| Male gender | 32 (55.2) | 55 (84.6) | 0.0006 |
| Race | |||
| Caucasian | 52 (89.7) | 20 (30.8) | <0.0001 |
| Black | 1 (1.7) | 37 (56.9) | |
| Other | 5 (8.6) | 8 (12.3) | |
| BMI | 25.2 (22.5–29.2) | 26.1 (23.3–28.8) | NS |
| Fibrosis | |||
| 0–2 | 45 (77.6) | 40 (61.5) | 0.0253 |
| 3–4 | 10 (17.2) | 24 (36.9) | |
| HCV genotype | |||
| Genotype 1 | 47 (81) | 56 (86.2) | NS |
| Genotype 2 & 3 | 11 (19) | 9 (14.8) | |
| ITPA deficiency | |||
| No deficiency | 35 (64) | 48 (76) | NS |
| Mild deficiency (>60% activity) | 8 (14) | 6 (10) | |
| Minimal activity (<30%) | 12 (22) | 9(14) | |
| IL28B CC genotype | 14 (24.1) | 18 (27.7) | NS |
| Baseline HCV RNA (log10 IU/ml) | 5.8 (5.4–6.2) | 6.3 (5.8–6.7) | <0.0001 |
| High viral load (>800,000) | 30 (52%) | 49 (75%) | 0.0083 |
| Baseline Hgb (g/dl) | 14.9 (13.7–16.0) | 14.2 (13.6–15.2) | NS |
| Baseline platelet count (×103/mm3) | 232 (180–279) | 205 (165–249) | NS |
| Baseline creatinine (mg/dl) | 0.96 (0.18) | 0.90 (0.14) | 0.038 |
| Baseline CD4 count | NA | 531 (356–772) | |
| Baseline HIV RNA (IU/ml) | NA | <50 (<50–107) | |
| Suppressed HIV RNA | NA | 47 (72.3) | |
| On HAART | NA | 54 (83.1) | |
| AZT containing HAART | NA | 10 (15.4) | |
| Erythropoietin use | NA | 22 (35%) | |
| Composite anemia at week 4 | 2/55 (3.6) | 12/63 (19) | 0.0106 |
| Composite anemia at week 12 | 4/55 (7.2) | 20/63 (31.8) | 0.0011 |
| Composite anemia at week 48 | 7/55 (12.7) | 29/63 (46) | 0.0001 |
| Overall SVR rates (%) | 20/51 (39) | 22/63 (35) | NS |
AZT, zidovudine; ABC, abacavir; HAART, highly active antiretroviral therapy; Hgb, hemoglobin.
Values are median (interquartile ranges) or (percentages). P-values: chi-square or Mann–Whitney tests.